BIA campaigns to improve access to new medicines in the NHS. While it is important that the UK has a supportive environment for bioscience companies, the ultimate aim is for patients to have access to life-saving or life-enhancing new medicines..
View more
Cell and gene therapies are a transformative new category of medicines whose full potential is only just beginning to emerge. Standard, small-molecule treatments are produced in a standardised fashion, and most are relatively short-lived within the body.
View more
Antimicrobial resistance (AMR) is when microbes, such as bacteria, viruses, and fungi, change over time and no longer respond to medicines designed to kill them.
View more
Animal research plays an invaluable and legally mandated part in developing medicines. It is essential - and a legal obligation – for researchers to ensure that promising new medicines are tested for safety and efficacy (i.e. having the intended effects) as far as possible before they are tested in humans.
View more
BIA are excited to announce the soft launch of our new website!
Our team is diligently working behind the scenes to enhance your browsing experience and provide you with valuable content. During this phase, you may encounter sections that are still under construction. We kindly ask for your patience as we finalise everything.
Thank you for visiting, and we thank you for your continuous support towards BIA.
